Welcome to our dedicated page for Tema Healthcare AI ETF news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Tema Healthcare AI ETF stock.
Cue Health Inc. news covered the company's healthcare technology business, including diagnostic-enabled care, at-home and point-of-care molecular testing, telehealth services, FDA-related product developments, earnings releases, and governance actions. Recurring updates described its COVID-19 and Mpox diagnostic products, customer categories across public agencies and private-sector healthcare users, and cost-reduction or operational efficiency actions.
Later Cue Health news documented the company's Chapter 7 bankruptcy filing and planned wind down, including the intended sale of assets and creditor-payment process under the Bankruptcy Code.
Cue Health (Nasdaq: HLTH) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time, in New York, NY. The event will be accessible via a live audio webcast and can be replayed for 180 days on the company’s website. Cue Health focuses on providing accessible health information and diagnostics, including a notable at-home COVID-19 test with FDA approval. Founded in 2010, the company is headquartered in San Diego.
On August 29, 2022, Cue Health Inc. (Nasdaq: HLTH) launched Cue Care™, a nationwide service providing same-day, at-home test-to-treatment solutions for COVID-19. Patients testing positive can consult healthcare professionals virtually, obtain e-prescriptions, and receive medication delivery, usually within hours, at a cost of $79 to $99. This service will soon extend to other diagnostic tests like flu and strep throat. Cue Health's COVID-19 test is noted for its accuracy, delivering results in 20 minutes and is endorsed by various prestigious organizations.
Cue Health Inc. (Nasdaq: HLTH) announced a collaboration with Fresenius Kidney Care on August 24, 2022, to deliver accurate COVID-19 self-testing for immunocompromised patients across several locations, including Hawaii and Puerto Rico. The initiative focuses on early detection to prevent complications and hospitalizations, particularly in remote areas. The Cue Health Monitoring System will be utilized for both in-center and at-home testing. This partnership aims to enhance patient access to timely diagnostics while ensuring confidence in testing accuracy.
Cue Health Inc. (Nasdaq: HLTH) announced the results of the largest clinical study on asymptomatic individuals, showing its COVID-19 test achieved a 99.4% accuracy compared to lab-based PCR tests. The study analyzed 3,037 samples, reporting 100% clinical sensitivity with no false negatives. Conducted at FH Health in Ontario, Canada, it highlights the test's rapid results (approximately 20 minutes) and potential to facilitate timely treatment while maintaining cost-effectiveness. The test is FDA authorized for professional and home use.
Cue Health Inc. (Nasdaq: HLTH) reported strong financial results for Q2 2022, boasting revenue of $87.7 million, surpassing expectations due to heightened COVID-19 test orders. The company shipped over 250,000 Cue Readers and is progressing with FDA submissions for flu and multiplex studies. Cue Health ended the quarter with $363.1 million in cash, while also initiating a $100 million secured credit facility. GAAP net income reflected a loss of $99.1 million primarily due to restructuring costs and elevated operating expenses.
Cue Health (NASDAQ: HLTH), a leader in healthcare technology, announced its participation in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. Cue Health provides individuals with easy access to health information and diagnostics, enabling effective health management. The company is recognized for its FDA-authorized at-home COVID-19 test and has received various international approvals, including CE mark in the EU and authorization from Health Canada and India. Founded in 2010, Cue is headquartered in San Diego.
Cue Health Inc. (NASDAQ: HLTH) is set to release its Q2 2022 financial results on August 10, 2022, at 1:30 p.m. PT. A conference call will be held to discuss these results and recent developments. Interested participants can register in advance to access the call and receive a unique PIN. Cue Health, established in 2010 and headquartered in San Diego, specializes in healthcare technology with a focus on providing accessible, lab-quality diagnostics. The company is known for its FDA-authorized at-home COVID-19 test.
Cue Health Inc. (Nasdaq: HLTH) announced the appointment of Allison Blackwell as Chief Human Resources Officer. With over 20 years in the healthcare sector, Blackwell previously held leadership roles at Danaher Corporation and Beckman Coulter. Her expertise includes human resources, diversity and inclusion, and employee relations. Blackwell aims to enhance Cue's HR strategies to support company objectives. CEO Ayub Khattak expressed confidence in her leadership to further Cue's mission of innovating healthcare delivery.
Cue Health (NASDAQ: HLTH), a healthcare technology company, has announced its management team's participation in two upcoming conferences. The first is the 43rd Annual Goldman Sachs Global Healthcare Conference on June 15, 2022, at 6:20 p.m. Eastern Time, held at the Terranea Resort, Rancho Palos Verdes. The second event is the 7th Annual Cowen FutureHealth Conference on June 22, 2022, at 1:35 p.m. Eastern Time. For further details and access to the presentations, visit www.cuehealth.com.
Cue Health Inc. (Nasdaq: HLTH) reported its first quarter 2022 financial results, achieving $179.4 million in revenue, up from $64.5 million in Q1 2021, marking a 178% year-over-year growth. This increase was driven by expanding the customer base and production capacity. Private sector revenue constituted 98% of total revenue. However, operating expenses rose significantly to $89.9 million, impacting net income which fell to $2.8 million from $13 million in the previous year. Cue also projects Q2 2022 revenues between $50 million and $55 million.